Keywords: Novogen, Triaxial Pharma, M&A, Teva, Procter & Gamble, OTC products sales, European Commission, Antitrust

Novogen to acquire Triaxial Pharma for $1.8 million; EU approves Teva/P&G deal

Article | 13 November 2012

Print This

Biotechnology firm Novogen (ASX: NRT) yesterday announced that it has signed a term sheet in relation to the proposed acquisition ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in